Biotech Values

[ThomasS]

MNTA: Can you read, please? There were two, separate, notes from Cowen today; I assume you left out the other for your own purposes?

1. Momenta Pharma thesis unchanged on Teva news, says Cowen
Cowen continues to believe Momenta's M-Enoxaprin is worth mid $20's to shares and reiterates its Outperform rating

2.“Teva could gain approval for generic Lovenox in the near- term,” Eric Schmidt, an analyst with Cowen & Co. in New York, said today in a note to clients. Teva’s FDA clearance could drive Momenta shares down as low as $8, he said.